Hepatotoxicity associated with statins
References
- 1. Bjørneboe M, Iversen O, Olsen S. Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period: incidence and prognosis. Acta Med Scand 1967;182:491-501. doi:
10.1111/j.0954-6820.1967.tb10873.x - 2. Malchow-Møller A, Matzen P, Bjerregaard B, Hilden J, Holst-Christensen J, Staehr JT, Altman L, Thomsen C, Juhl E. Causes and characteristics of 500 consecutive causes of jaundice. Scand J Gastroenterol 1981;16:1-6. PMID: 7233075
- 3. Whitehead MW, Hainsworth I, Kingham JG. The causes of obvious jaundice in South West Wales: perceptions versus reality. Gut 2001;48:409-13. doi:
10.1136/gut.48.3.409 - 4. Björnsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003;38:86-94. doi:
10.1080/00365520310000492 - 5. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SHB, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-54. doi:
10.7326/0003-4819-137-12-200212170-00007 - 6. Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis 1996;16:343-8. doi:
10.1055/s-2007-1007247 - 7. Wei G, Bergqvist A, Broome U, Björnsson E. Acute liver failure in Sweden: etiology and prognosis. Scand J Gastroenterol 2004;39(Suppl 240):48A.
- 8. O'Grady JG, Alexander GJM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45. doi:
10.1016/0016- 5085(89)90081-4 - 9. Hoofnagle JH, Carithers RL Jr, Shapiro C, Nascher H. Fulminant hepatic failure: summary of a workshop. Hepatology 1995;21:240-52. doi:
10.1016/0270- 9139(95)90434-4 - 10. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharm Therap 1995;58:108-17. doi:
10.1016/0009-9236(95)90078-0 - 11. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000;4:73-96. PMID: 11232192
- 12. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975;69:289-302. PMID: 1150039
- 13. Senior JR. Regulatory perspectives. In: Kaplowitz N, DeLeve D, editors. Drug-induced liver disease. New York: Marcel Dekker; 2003. p. 739-54.
- 14. Zimmerman HJ. Drug-induced liver disease. In: Sciff ER, Sorrell MF, Maddrey WC, editors. Sciff′s diseases of the liver. 8th edition. Philadelphia: Lippincott-Raven Publishers; 1999. p. 973-1064.
- 15. Pillans PI. Drug associated hepatic reactions in New Zealand: 21-years’ experience. N Z Med J 1996;109:315-9. PMID: 8816722
- 16. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992;232:133-8. doi:
10.1111/j.1365-2796.1992.tb00562.x - 17. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418. doi:
10.2165/0129784-200808060-0000 - 18. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-9. doi:
10.1002/hep.20800 - 19. Kshirsagar A, Vetal Y, Ashok P, Bhosle P, Ingawale D. Drug induced hepatotoxicity: a comprehensive review. Internet J Pharmacol 2008 [displayed 18 October 2017]. Available at http://ispub.com/IJPHARM/7/1/3723
- 20. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97(Suppl 1):77C-81C. doi:
10.1016/j.amjcard.2005.12.014 - 21. Bhardwaj SS, Chalasani N. Lipid lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 2007;11:597-613. doi:
10.1016/j.cld.2007.06.010 - 22. Kubota T, Fujisaki K, Itoh Y, Yano T, Sendo T, Oishi R. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol 2004;67:2175-86. doi:
10.1016/j.bcp.2004.02.037 - 23. Wolters LMM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 2005;17:589-90. PMID: 15827453
- 24. Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepat 2014;60:679-86. doi:
10.1002/hep.27157 - 25. Kubatka P, Kruzliak P, Rotrekl V, Jelinkova S, Mladosievicova B. Statins in oncological research: from experimental studies to clinical practice. Crit Rev Oncol Hematol 2014;92:296-311. doi:
10.1016/j.critrevonc.2014.08.002 - 26. Cueto R, Valdivielso P, Lucena MI, Garcίa-Arias C, Andrade RJ, Gonzάlez-Santos P. Statins: hepatic disease and hepatotoxicity risk. Open Gastroenterol J 2008;2:18-23. doi:
10.2174/1874259900802010018 - 27. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepat 2005;41:690-5. doi:
10.1002/hep.20671 - 28. Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. Gastroenterol Hepatol 2013;9:605-6. PMCID: PMC3983981
- 29. Abdoli N, Azarmi Y, Eghbal MA. Protective effects of N-acetylcysteine against the statins cytotoxicity in freshly isolated rat hepatocytes. Adv Pharm Bull 2014;4:249-54. doi:
10.5681/apb.2014.036 - 30. Tolosa L, Carmona A, Castell JV, Gόmez-Lechόn MJ, Donato MT. High-content screening of drug-induced mitocondrial impairment in hepatic cells: effects of statins. Arch Toxicol 2015;89:1847-60. doi:
10.1007/s00204-014-1334-3 - 31. Ciba M, Ak M, Karahalil B. Alpha-glutathione-s-transferase can be a biomarker for both drug-related toxicity as well as individual susceptibility. Minerva Psichiatr 2016;57:62-71.
- 32. Abdoli N, Heidari R, Azarmi Y, Eghbal MA. Mechanism of the statins cytotoicity in freshly isolated rat hepatocytes. J Biochem Molecular Toxicol 2013;27:287-94. doi:
10.1002/ jbt21485 - 33. Haque T, Sasatomi E, Hayashi PH. Drug-induced liver injury: Pattern recognition and future directions. Gut Liver 2016;10:27-36. doi:
10.5009/gnl15114 - 34. Fitchett DH, Hegele RA, Verma S. Cardiology patient page. Statin intolerance. Circulation 2015;131:e389-91. doi:
10.1161/CIRCULATIONAHA.114.013189 - 35. Wang LY, Huang Y, Perng C, Huang B, Lin H. Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis. Br J Clin Pharmacol 2016;82:823-30. doi:
10.1111/bcp.13009 - 36. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24:584-91. doi:
10.1592/phco.24.6.584.34738 - 37. Bradford RH, Shear CL, Achanassios N, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9. doi:
10.1001/archinte.1991.00400010067008 - 38. Roberts WC. Getting more people on statins. Am J Cardiol 2002;90:683-5. doi:
10.1016/S0002-9149(02)02590-0 - 39. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80. doi:
10.1016/S0002-9149(02)02355-X - 40. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmöller J. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterollowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003;74:186-94. doi:
10.1016/S0009-9236(03)00121-8 - 41. Flockhart DA, Rae JM. Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenom J 2003;3:3-5. doi:
10.1038/sj.tpj.6500144 - 42. Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246-59. doi:
10.1053/j.gastro.2010.04.001 - 43. Zhong G, Liu Y, Ye Y, Hao F, Wang K, Gong J. Meta-analysis of studies using statins as a reducer for primary liver cancer risk. Sci Rep 2016;26256-65. doi:
10.1038/srep26256 - 44. Licata A, Minissale MG, Calvaruso V, Craxì A. A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort. Eur Rev Med Pharmacol Sci 2017;21(Suppl 1):112-21. PMID: 28379588
- 45. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:374-80. doi:
10.1016/j. jhep.2011.07.023 - 46. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014;89:95-106. doi:
10.1016/j. mayocp.2013.09.016 - 47. Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, Moretti U, Moore N, De Ponti F. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol 2015;80:285-93. doi:
10.1111/bcp.12611 - 48. Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol 2015;89:327-34. doi:
10.1007/s00204-015-1456-2 - 49. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009;29:412-22. doi:
10.1055/s-0029-1240010 - 50. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005;118:618-24. doi:
10.1016/j.amjmed.2005.02.008 - 51. Perdices EV, Medina-Cáliz I, Hernando S, Ortega A, Martín- Ocaña F, Navarro JM, Peláez G, Castiella A, Hallal H, Romero-Gómez M, González-Jiménez A, Robles-Díaz M, Lucena MI, Andrade RJ. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig 2014;106:246-54. PMID: 25075655
- 52. Chang CH, Chang YC, Lee YC, Liu YC, Chuang LM, Lin JW. Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population- based cohort study. J Gastroenterol Hepatol 2015;30:155-62. doi:
10.1111/jgh.12657 - 53. Younoszai Z, Li Z, Stepanova M, Erario M, Cable R, Younossi ZM. Statin use is not associated with liver related mortality. Ann Hepatol 2014;13:84-90. doi:
10.1007/s11274- 015-1903-5 - 54. Rangnekar AS, Fontana RJ. An update on drug induced liver injury. Minerva Gastroenterol Dietol 2011;57:213-29. PMID: 21587150
- 55. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007;6:673-84. doi:
10.1517/14740338.6.6.673
Language: English, Croatian, Slovenian
Page range: 254 - 260
Submitted on: May 1, 2017
Accepted on: Oct 1, 2017
Published on: Jan 13, 2018
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2018 Bensu Karahalil, Emine Hare, Göksel Koç, İrem Uslu, Kerem Şentürk, Yağmur Özkan, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.